ANI PHARMACEUTICALS INC (ANIP) FY2025 10-K Annual Report
ANI PHARMACEUTICALS INC (ANIP) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 27, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
ANI PHARMACEUTICALS INC FY2025 10-K Analysis
Business Overview
- • Core business model: developing, manufacturing, commercializing therapeutics via Rare Disease, Generics, and Brands segments
- • Acquired Alimera Sciences on September 16, 2024, adding ILUVIEN® and YUTIQ® products
- • Strategic expansion into ophthalmic specialty products through acquisition
- • Acquisition introduces new product lines, diversifying portfolio beyond prior scope
Management Discussion & Analysis
- • Total revenue details not provided for FY 2024; Alimera acquisition adds ILUVIEN® and YUTIQ® franchises
- • No specific operating margin or profitability figures mentioned in the available excerpt
- • No segment-specific revenue or profit data disclosed
- • Sale of Oakville facility for $14.2 million completed in March 2024; no other cash flow or capital allocation details given
- • Management highlights growth via ILUVIEN label expansion and Alimera acquisition; no formal guidance or risk outlook stated
Risk Factors
- • Regulatory/legal risk: Compliance with Medicaid Drug Rebate Program risks material penalties due to increased rebate accruals from branded and authorized generic products
- • Geopolitical/macro risk: 17% of raw materials/API from one domestic supplier in 2025; supply disruption risk from FDA inspections and trade or geopolitical tensions
- • Operational/supply chain risk: Reliance on single-source third-party contract manufacturers for Cortrophin Gel and ILUVIEN, risking commercialization delays if noncompliant or unavailable
- • Competitive risk: Dependence on Cortrophin Gel, competing with major pharma companies and generics that may have fewer side effects and higher physician acceptance
- • Financial/structural risk: 2024 Credit Agreement contains restrictive financial covenants, with potential for accelerated debt repayment and termination if breached
ANI PHARMACEUTICALS INC FY2025 Key Financial MetricsXBRL
Revenue
$883M
▲ +43.8% YoY
Net Income
$78M
▲ +522.9% YoY
Operating Margin
12.6%
▲ +1248bp YoY
Net Margin
8.9%
▲ +1188bp YoY
ROE
14.5%
▲ +1908bp YoY
Total Assets
$1.4B
▲ +12.2% YoY
EPS (Diluted)
$3.32
▲ +419.2% YoY
Operating Cash Flow
$185M
▲ +189.3% YoY
Source: XBRL data from ANI PHARMACEUTICALS INC FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on ANI PHARMACEUTICALS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.